To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research November 22, 2022November 22, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: To Develop Japan’s First Blood Biomarker-Based…Creating New Value from a New, Cutting-edge, Global…Rakuten Medical and Shimadzu Corporation announce a…Rakuten Medical and Shimadzu Corporation announce a…Mass spectrometry technology contributed to a…Roche announces positive data from broad blood…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
